Premium
Behind‐the‐Counter Statins: A Silver Bullet for Reducing Costs and Increasing Access?
Author(s) -
Sood Neeraj,
Sun Eric,
Zhuo Xiaohui
Publication year - 2012
Publication title -
health services research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.706
H-Index - 121
eISSN - 1475-6773
pISSN - 0017-9124
DOI - 10.1111/j.1475-6773.2011.01315.x
Subject(s) - simvastatin , medicine , medical prescription , confounding , difference in differences , economics , econometrics , pharmacology
Objective To examine how the 2004 introduction of behind‐the‐counter ( BTC ) simvastatin in the United Kingdom affected utilization, prices, and expenditures. Data Sources/Study Setting Secondary data on simvastatin utilization, prices, and expenditures between 1997 and 2007 in the United Kingdom and four other countries. Study Design We used a difference‐in‐differences approach to estimate how the introduction of BTC simvastatin affected utilization, prices, and expenditures. This approach compares outcomes in the United Kingdom before and after the introduction of BTC simvastatin, using outcomes in countries where the drug remained prescription only to control for possible confounders. Data Collection/Extraction Methods Data on simvastain utilization, prices, and expenditures between 1997 and 2007 in the United Kingdom and four other countries were obtained from an outside vendor. Principal Findings The introduction of BTC simvastatin in the United Kingdom led to a significant increase in utilization of simvastatin and a significant decline in expenditures for simvastatin purchases. Our results are robust to alternate model specifications. Conclusions Behind‐the‐counter statins have the potential to simultaneously increase use of statins and lower expenditures.